nach oben

Reviews in Endocrine and Metabolic Disorders

Erschienen in:

01.03.2014

Regulation of pyruvate metabolism in metabolic-related diseases

verfasst von: Nam Ho Jeoung, Chris R. Harris, Robert A. Harris

Erschienen in: Reviews in Endocrine and Metabolic Disorders | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

Pyruvate is an obligatory intermediate in the oxidative disposal of glucose and a major precursor for the synthesis of glucose, glycerol, fatty acids, and non-essential amino acids. Stringent control of the fate of pyruvate is critically important for cellular homeostasis. The regulatory mechanisms for its metabolism are therefore of great interest. Recent advances include the findings that (a) the mitochondrial pyruvate carrier is sensitive to inhibition by thiazolidinediones; (b) pyruvate dehydrogenase kinases induce the Warburg effect in many disease states; and (c) pyruvate carboxylase is an important determinate of the rates of gluconeogenesis in humans with type 2 diabetes. These enzymes are potential therapeutic targets for several diseases.

Halestrap AP, Denton RM. Specific inhibition of pyruvate transport in rat liver mitochondria and human erythrocytes by alpha-cyano-4-hydroxycinnamate. Biochem J. 1974;138(2):313–6.PubMed

Halestrap AP, Wilson MC. The monocarboxylate transporter family–role and regulation. IUBMB Life. 2012;64(2):109–19.PubMed

Thomas AP, Halestrap AP. Identification of the protein responsible for pyruvate transport into rat liver and heart mitochondria by specific labelling with [3H]N-phenylmaleimide. Biochem J. 1981;196(2):471–9.PubMed

Bricker DK, Taylor EB, Schell JC, Orsak T, Boutron A, Chen YC, et al. A mitochondrial pyruvate carrier required for pyruvate uptake in yeast, Drosophila, and humans. Science. 2012;337(6090):96–100.PubMedCentralPubMed

Herzig S, Raemy E, Montessuit S, Veuthey JL, Zamboni N, Westermann B, et al. Identification and functional expression of the mitochondrial pyruvate carrier. Science. 2012;337(6090):93–6.PubMed

Henry RR, Erickson D, Ciaraldi TP. PPARg agonists and the future for insulin sensitizers: a report of a debate and presentations on the subject at the 72nd Scientific Sessions of the American Diabetes Association, Philadelpia, 8–12 June, 2012. Br J Diabetes Vasc Dis. 2012;12(4):206–10.

Birnbaum Y, Long B, Qian J, Perez-Polo JR, Ye Y. Pioglitazone limits myocardial infarct size, activates Akt, and upregulates cPLA2 and COX-2 in a PPAR-gamma-independent manner. Basic Res Cardiol. 2011;106(3):431–46.PubMed

Chen Z, Vigueira PA, Chambers KT, Hall AM, Mitra MS, Qi N, et al. Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor gamma-sparing thiazolidinedione. J Biol Chem. 2012;287(28):23537–48.PubMed

Feinstein DL, Spagnolo A, Akar C, Weinberg G, Murphy P, Gavrilyuk V, et al. Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key? Biochem Pharmacol. 2005;70(2):177–88.PubMed

10.

LeBrasseur NK, Kelly M, Tsao TS, Farmer SR, Saha AK, Ruderman NB, et al. Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues. Am J Physiol Endocrinol Metab. 2006;291(1):E175–81.PubMed

11.

Norris AW, Chen L, Fisher SJ, Szanto I, Ristow M, Jozsi AC, et al. Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J Clin Invest. 2003;112(4):608–18.PubMedCentralPubMed

12.

Thal SC, Heinemann M, Luh C, Pieter D, Werner C, Engelhard K. Pioglitazone reduces secondary brain damage after experimental brain trauma by PPAR-gamma-independent mechanisms. J Neurotrauma. 2011;28(6):983–93.PubMed

13.

Wei S, Kulp SK, Chen CS. Energy restriction as an antitumor target of thiazolidinediones. J Biol Chem. 2010;285(13):9780–91.PubMed

14.

Colca JR, VanderLugt JT, Adams WJ, Shashlo A, McDonald WG, Liang J, et al. Clinical proof-of-concept study with MSDC-0160, a prototype mTOT-modulating insulin sensitizer. Clin Pharmacol Ther. 2013;93(4):352–9.PubMedCentralPubMed

15.

Colca JR, McDonald WG, Cavey GS, Cole SL, Holewa DD, Brightwell-Conrad AS, et al. Identification of a mitochondrial target of thiazolidinedione insulin sensitizers (mTOT)–relationship to newly identified mitochondrial pyruvate carrier proteins. PLoS One. 2013;8(5):e61551.PubMedCentralPubMed

16.

Divakaruni AS, Wiley SE, Rogers GW, Andreyev AY, Petrosyan S, Loviscach M, et al. Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier. Proc Natl Acad Sci U S A. 2013;110(14):5422–7.PubMedCentralPubMed

17.

Kaplan RS, Mayor JA, Blackwell R, Maughon RH, Wilson GL. The effect of insulin supplementation on diabetes-induced alterations in the extractable levels of functional mitochondrial anion transport proteins. Arch Biochem Biophys. 1991;287(2):305–11.PubMed

18.

Harris RA, Bowker-Kinley MM, Huang B, Wu P. Regulation of the activity of the pyruvate dehydrogenase complex. Adv Enzym Regul. 2002;42:249–59.

19.

Holness MJ, Sugden MC. Regulation of pyruvate dehydrogenase complex activity by reversible phosphorylation. Biochem Soc Trans. 2003;31(Pt 6):1143–51.PubMed

20.

Randle PJ. Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years. Diabetes Metab Rev. 1998;14(4):263–83.PubMed

21.

Bowker-Kinley MM, Davis WI, Wu P, Harris RA, Popov KM. Evidence for existence of tissue-specific regulation of the mammalian pyruvate dehydrogenase complex. Biochem J. 1998;329(Pt 1):191–6.PubMed

22.

Bao H, Kasten SA, Yan X, Roche TE. Pyruvate dehydrogenase kinase isoform 2 activity limited and further inhibited by slowing down the rate of dissociation of ADP. Biochemistry. 2004;43(42):13432–41.PubMed

23.

Wu P, Blair PV, Sato J, Jaskiewicz J, Popov KM, Harris RA. Starvation increases the amount of pyruvate dehydrogenase kinase in several mammalian tissues. Arch Biochem Biophys. 2000;381(1):1–7.PubMed

24.

Attia RR, Sharma P, Janssen RC, Friedman JE, Deng X, Lee JS, et al. Regulation of pyruvate dehydrogenase kinase 4 (PDK4) by CCAAT/enhancer-binding protein beta (C/EBPbeta). J Biol Chem. 2011;286(27):23799–807.PubMed

25.

Huang B, Wu P, Bowker-Kinley MM, Harris RA. Regulation of pyruvate dehydrogenase kinase expression by peroxisome proliferator-activated receptor-alpha ligands, glucocorticoids, and insulin. Diabetes. 2002;51(2):276–83.PubMed

26.

Kwon HS, Huang B, Unterman TG, Harris RA. Protein kinase B-alpha inhibits human pyruvate dehydrogenase kinase-4 gene induction by dexamethasone through inactivation of FOXO transcription factors. Diabetes. 2004;53(4):899–910.PubMed

27.

Chokkalingam K, Jewell K, Norton L, Littlewood J, van Loon LJ, Mansell P, et al. High-fat/low-carbohydrate diet reduces insulin-stimulated carbohydrate oxidation but stimulates nonoxidative glucose disposal in humans: an important role for skeletal muscle pyruvate dehydrogenase kinase 4. J Clin Endocrinol Metab. 2007;92(1):284–92.PubMed

28.

Holness MJ, Kraus A, Harris RA, Sugden MC. Targeted upregulation of pyruvate dehydrogenase kinase (PDK)-4 in slow-twitch skeletal muscle underlies the stable modification of the regulatory characteristics of PDK induced by high-fat feeding. Diabetes. 2000;49(5):775–81.PubMed

29.

Kim YI, Lee FN, Choi WS, Lee S, Youn JH. Insulin regulation of skeletal muscle PDK4 mRNA expression is impaired in acute insulin-resistant states. Diabetes. 2006;55(8):2311–7.PubMed

30.

Pehleman TL, Peters SJ, Heigenhauser GJ, Spriet LL. Enzymatic regulation of glucose disposal in human skeletal muscle after a high-fat, low-carbohydrate diet. J Appl Physiol (1985). 2005;98(1):100–7.

31.

Peters SJ, Harris RA, Wu P, Pehleman TL, Heigenhauser GJ, Spriet LL. Human skeletal muscle PDH kinase activity and isoform expression during a 3-day high-fat/low-carbohydrate diet. Am J Physiol Endocrinol Metab. 2001;281(6):E1151–8.PubMed

32.

Tao R, Xiong X, Harris RA, White MF, Dong XC. Genetic inactivation of pyruvate dehydrogenase kinases improves hepatic insulin resistance induced diabetes. PLoS One. 2013;8(8):e71997.PubMedCentralPubMed

33.

Hwang B, Jeoung NH, Harris RA. Pyruvate dehydrogenase kinase isoenzyme 4 (PDHK4) deficiency attenuates the long-term negative effects of a high-saturated fat diet. Biochem J. 2009;423(2):243–52.PubMed

34.

Jeoung NH, Harris RA. Pyruvate dehydrogenase kinase-4 deficiency lowers blood glucose and improves glucose tolerance in diet-induced obese mice. Am J Physiol Endocrinol Metab. 2008;295(1):E46–54.PubMed

35.

Jeoung NH, Wu P, Joshi MA, Jaskiewicz J, Bock CB, Depaoli-Roach AA, et al. Role of pyruvate dehydrogenase kinase isoenzyme 4 (PDHK4) in glucose homoeostasis during starvation. Biochem J. 2006;397(3):417–25.PubMed

36.

Huang J, Jones D, Luo B, Sanderson M, Soto J, Abel ED, et al. Iron overload and diabetes risk: a shift from glucose to Fatty Acid oxidation and increased hepatic glucose production in a mouse model of hereditary hemochromatosis. Diabetes. 2011;60(1):80–7.PubMed

37.

Kim YD, Kim YH, Tadi S, Yu JH, Yim YH, Jeoung NH, et al. Metformin inhibits growth hormone-mediated hepatic PDK4 gene expression through induction of orphan nuclear receptor small heterodimer partner. Diabetes. 2012;61(10):2484–94.PubMed

38.

Connaughton S, Chowdhury F, Attia RR, Song S, Zhang Y, Elam MB, et al. Regulation of pyruvate dehydrogenase kinase isoform 4 (PDK4) gene expression by glucocorticoids and insulin. Mol Cell Endocrinol. 2010;315(1–2):159–67.PubMedCentralPubMed

39.

Puthanveetil P, Wang Y, Wang F, Kim MS, Abrahani A, Rodrigues B. The increase in cardiac pyruvate dehydrogenase kinase-4 after short-term dexamethasone is controlled by an Akt-p38-forkhead box other factor-1 signaling axis. Endocrinology. 2010;151(5):2306–18.PubMed

40.

Jeoung NH, Rahimi Y, Wu P, Lee WN, Harris RA. Fasting induces ketoacidosis and hypothermia in PDHK2/PDHK4-double-knockout mice. Biochem J. 2012;443(3):829–39.PubMed

41.

Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309–14.PubMed

42.

Freed-Pastor WA, Prives C. Mutant p53: one name, many proteins. Genes Dev. 26(12):1268–86.

43.

Contractor T, Harris CR. p53 negatively regulates transcription of the pyruvate dehydrogenase kinase Pdk2. Cancer Res. 2012;72(2):560–7.PubMed

44.

Bensaad K, Vousden KH. Savior and slayer: the two faces of p53. Nat Med. 2005;11(12):1278–9.PubMed

45.

Hsieh MC, Das D, Sambandam N, Zhang MQ, Nahle Z. Regulation of the PDK4 isozyme by the Rb-E2F1 complex. J Biol Chem. 2008;283(41):27410–7.PubMed

46.

Sameen S, Khalid Z, Malik SI. Role of pyruvate dehydrogenase kinases (PDK’s) and their respective microRNA’s in human ovarian cancer. J Med Gen Genomics. 2011;3(7):115–21.

47.

Bonnet S, Archer SL, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R, et al. A mitochondria-K + channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell. 2007;11(1):37–51.PubMed

48.

Sutendra G, Michelakis ED. Pyruvate dehydrogenase kinase as a novel therapeutic target in oncology. Front Oncol. 2013;3:38.PubMedCentralPubMed

49.

Kim JW, Gao P, Liu YC, Semenza GL, Dang CV. Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol Cell Biol. 2007;27(21):7381–93.PubMedCentralPubMed

50.

Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 2006;3(3):177–85.PubMed

51.

Papandreou I, Cairns RA, Fontana L, Lim AL, Denko NC. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab. 2006;3(3):187–97.PubMed

52.

Kluza J, Corazao-Rozas P, Touil Y, Jendoubi M, Maire C, Guerreschi P, et al. Inactivation of the HIF-1alpha/PDK3 signaling axis drives melanoma toward mitochondrial oxidative metabolism and potentiates the therapeutic activity of pro-oxidants. Cancer Res. 2012;72(19):5035–47.PubMed

53.

Lu CW, Lin SC, Chen KF, Lai YY, Tsai SJ. Induction of pyruvate dehydrogenase kinase-3 by hypoxia-inducible factor-1 promotes metabolic switch and drug resistance. J Biol Chem. 2008;283(42):28106–14.PubMed

54.

Jones RG, Thompson CB. Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev. 2009;23(5):537–48.PubMed

55.

Faubert B, Boily G, Izreig S, Griss T, Samborska B, Dong Z, et al. AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metab. 2013;17(1):113–24.PubMedCentralPubMed

56.

Wu CA, Chao Y, Shiah SG, Lin WW. Nutrient deprivation induces the Warburg effect through ROS/AMPK-dependent activation of pyruvate dehydrogenase kinase. Biochim Biophys Acta. 2013;1833(5):1147–56.PubMed

57.

Grassian AR, Metallo CM, Coloff JL, Stephanopoulos G, Brugge JS. Erk regulation of pyruvate dehydrogenase flux through PDK4 modulates cell proliferation. Genes Dev. 2011;25(16):1716–33.PubMed

58.

Kamarajugadda S, Stemboroski L, Cai Q, Simpson NE, Nayak S, Tan M, et al. Glucose oxidation modulates anoikis and tumor metastasis. Mol Cell Biol. 2012;32(10):1893–907.PubMedCentralPubMed

59.

Lee JH, Kim EJ, Kim DK, Lee JM, Park SB, Lee IK, et al. Hypoxia induces PDK4 gene expression through induction of the orphan nuclear receptor ERRgamma. PLoS One. 2012;7(9):e46324.PubMedCentralPubMed

60.

Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer. 2011;11(2):85–95.PubMed

61.

Cheung TH, Rando TA. Molecular regulation of stem cell quiescence. Nat Rev Mol Cell Biol. 2013;14(6):329–40.PubMed

62.

Simsek T, Kocabas F, Zheng J, Deberardinis RJ, Mahmoud AI, Olson EN, et al. The distinct metabolic profile of hematopoietic stem cells reflects their location in a hypoxic niche. Cell Stem Cell. 2010;7(3):380–90.PubMed

63.

Takubo K, Goda N, Yamada W, Iriuchishima H, Ikeda E, Kubota Y, et al. Regulation of the HIF-1alpha level is essential for hematopoietic stem cells. Cell Stem Cell. 2010;7(3):391–402.PubMed

64.

Suda T, Takubo K, Semenza GL. Metabolic regulation of hematopoietic stem cells in the hypoxic niche. Cell Stem Cell. 2011;9(4):298–310.PubMed

65.

Takubo K, Nagamatsu G, Kobayashi CI, Nakamura-Ishizu A, Kobayashi H, Ikeda E, et al. Regulation of glycolysis by Pdk functions as a metabolic checkpoint for cell cycle quiescence in hematopoietic stem cells. Cell Stem Cell. 2013;12(1):49–61.PubMed

66.

Kong SW, Bodyak N, Yue P, Liu Z, Brown J, Izumo S, et al. Genetic expression profiles during physiological and pathological cardiac hypertrophy and heart failure in rats. Physiol Genomics. 2005;21(1):34–42.PubMed

67.

Arikawa E, Ma RC, Isshiki K, Luptak I, He Z, Yasuda Y, et al. Effects of insulin replacements, inhibitors of angiotensin, and PKCbeta’s actions to normalize cardiac gene expression and fuel metabolism in diabetic rats. Diabetes. 2007;56(5):1410–20.PubMed

68.

Herrema H, Derks TG, van Dijk TH, Bloks VW, Gerding A, Havinga R, et al. Disturbed hepatic carbohydrate management during high metabolic demand in medium-chain acyl-CoA dehydrogenase (MCAD)-deficient mice. Hepatology. 2008;47(6):1894–904. doi:10.1002/hep.22284.PubMed

69.

Chambers KT, Leone TC, Sambandam N, Kovacs A, Wagg CS, Lopaschuk GD, et al. Chronic inhibition of pyruvate dehydrogenase in heart triggers an adaptive metabolic response. J Biol Chem. 2011;286(13):11155–62.PubMed

70.

Zhao G, Jeoung NH, Burgess SC, Rosaaen-Stowe KA, Inagaki T, Latif S, et al. Overexpression of pyruvate dehydrogenase kinase 4 in heart perturbs metabolism and exacerbates calcineurin-induced cardiomyopathy. Am J Physiol Heart Circ Physiol. 2008;294(2):H936–43.PubMed

71.

Fillmore N, Lopaschuk GD. Targeting mitochondrial oxidative metabolism as an approach to treat heart failure. Biochim Biophys Acta. 2013;1833(4):857–65.PubMed

72.

Ussher JR, Wang W, Gandhi M, Keung W, Samokhvalov V, Oka T, et al. Stimulation of glucose oxidation protects against acute myocardial infarction and reperfusion injury. Cardiovasc Res. 2012;94(2):359–69.PubMed

73.

Korotchkina LG, Sidhu S, Patel MS. R-lipoic acid inhibits mammalian pyruvate dehydrogenase kinase. Free Radic Res. 2004;38(10):1083–92.PubMed

74.

Onay-Besikci A, Wagg C, Lopaschuk TP, Keung W, Lopaschuk GD. Alpha-lipoic acid increases cardiac glucose oxidation independent of AMP-activated protein kinase in isolated working rat hearts. Basic Res Cardiol. 2007;102(5):436–44.PubMed

75.

Mori J, Basu R, McLean BA, Das SK, Zhang L, Patel VB, et al. Agonist-induced hypertrophy and diastolic dysfunction are associated with selective reduction in glucose oxidation: a metabolic contribution to heart failure with normal ejection fraction. Circ Heart Fail. 2012;5(4):493–503.PubMed

76.

Mori J, Alrob OA, Wagg CS, Harris RA, Lopaschuk GD, Oudit GY. ANG II causes insulin resistance and induces cardiac metabolic switch and inefficiency: a critical role of PDK4. Am J Physiol Heart Circ Physiol. 2013;304(8):H1103–13.PubMed

77.

Erickson JR, Joiner ML, Guan X, Kutschke W, Yang J, Oddis CV, et al. A dynamic pathway for calcium-independent activation of CaMKII by methionine oxidation. Cell. 2008;133(3):462–74.PubMedCentralPubMed

78.

Luo M, Guan X, Luczak ED, Lang D, Kutschke W, Gao Z, et al. Diabetes increases mortality after myocardial infarction by oxidizing CaMKII. J Clin Invest. 2013;123(3):1262–74.PubMedCentralPubMed

79.

Ozcan L, Wong CC, Li G, Xu T, Pajvani U, Park SK, et al. Calcium signaling through CaMKII regulates hepatic glucose production in fasting and obesity. Cell Metab. 2012;15(5):739–51.PubMedCentralPubMed

80.

Tao L, Xie Q, Ding YH, Li ST, Peng S, Zhang YP, et al. CAMKII and Calcineurin regulate the lifespan of Caenorhabditis elegans through the FOXO transcription factor DAF-16. Elife. 2013;2:e00518.PubMedCentralPubMed

81.

Meurs KM, Lahmers S, Keene BW, White SN, Oyama MA, Mauceli E, et al. A splice site mutation in a gene encoding for PDK4, a mitochondrial protein, is associated with the development of dilated cardiomyopathy in the Doberman pinscher. Hum Genet. 2012;131(8):1319–25.PubMed

82.

Ferreira AV, Segatto M, Menezes Z, Macedo AM, Gelape C, de Oliveira Andrade L, et al. Evidence for Trypanosoma cruzi in adipose tissue in human chronic Chagas disease. Microbes Infect. 2011;13(12–13):1002–5.PubMedCentralPubMed

83.

Garg N, Gerstner A, Bhatia V, DeFord J, Papaconstantinou J. Gene expression analysis in mitochondria from chagasic mice: alterations in specific metabolic pathways. Biochem J. 2004;381(Pt 3):743–52.PubMed

84.

Caradonna KL, Engel JC, Jacobi D, Lee CH, Burleigh BA. Host metabolism regulates intracellular growth of Trypanosoma cruzi. Cell Host Microbe. 2013;13(1):108–17.PubMedCentralPubMed

85.

Piao L, Sidhu VK, Fang YH, Ryan JJ, Parikh KS, Hong Z, et al. FOXO1-mediated upregulation of pyruvate dehydrogenase kinase-4 (PDK4) decreases glucose oxidation and impairs right ventricular function in pulmonary hypertension: therapeutic benefits of dichloroacetate. J Mol Med (Berl). 2013;91(3):333–46.

86.

Mallinson JE, Constantin-Teodosiu D, Glaves PD, Martin EA, Davies WJ, Westwood FR, et al. Pharmacological activation of the pyruvate dehydrogenase complex reduces statin-mediated upregulation of FOXO gene targets and protects against statin myopathy in rodents. J Physiol. 2012;590(Pt 24):6389–402.PubMed

87.

Wang Y, Liu W, Masuyama R, Fukuyama R, Ito M, Zhang Q, et al. Pyruvate dehydrogenase kinase 4 induces bone loss at unloading by promoting osteoclastogenesis. Bone. 2012;50(1):409–19.PubMed

88.

Kennerson ML, Yiu EM, Chuang DT, Kidambi A, Tso SC, Ly C, et al. A new locus for X-linked dominant Charcot-Marie-Tooth disease (CMTX6) is caused by mutations in the pyruvate dehydrogenase kinase isoenzyme 3 (PDK3) gene. Hum Mol Genet. 2013;22(7):1404–16.PubMed

89.

Caruso M, Maitan MA, Bifulco G, Miele C, Vigliotta G, Oriente F, et al. Activation and mitochondrial translocation of protein kinase Cdelta are necessary for insulin stimulation of pyruvate dehydrogenase complex activity in muscle and liver cells. J Biol Chem. 2001;276(48):45088–97.PubMed

90.

Churchill EN, Murriel CL, Chen CH, Mochly-Rosen D, Szweda LI. Reperfusion-induced translocation of deltaPKC to cardiac mitochondria prevents pyruvate dehydrogenase reactivation. Circ Res. 2005;97(1):78–85.PubMed

91.

Acin-Perez R, Hoyos B, Zhao F, Vinogradov V, Fischman DA, Harris RA, et al. Control of oxidative phosphorylation by vitamin A illuminates a fundamental role in mitochondrial energy homoeostasis. FASEB J. 2010;24(2):627–36.PubMed

92.

Gong J, Hoyos B, Acin-Perez R, Vinogradov V, Shabrova E, Zhao F, et al. Two protein kinase C isoforms, delta and epsilon, regulate energy homeostasis in mitochondria by transmitting opposing signals to the pyruvate dehydrogenase complex. FASEB J. 2012;26(8):3537–49.PubMed

93.

Hoshi M, Takashima A, Noguchi K, Murayama M, Sato M, Kondo S, et al. Regulation of mitochondrial pyruvate dehydrogenase activity by tau protein kinase I/glycogen synthase kinase 3beta in brain. Proc Natl Acad Sci U S A. 1996;93(7):2719–23.PubMedCentralPubMed

94.

McBride HM, Neuspiel M, Wasiak S. Mitochondria: more than just a powerhouse. Curr Biol. 2006;16(14):R551–60.PubMed

95.

Hitosugi T, Fan J, Chung TW, Lythgoe K, Wang X, Xie J, et al. Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolism. Mol Cell. 2011;44(6):864–77.PubMedCentralPubMed

96.

Jitrapakdee S, St Maurice M, Rayment I, Cleland WW, Wallace JC, Attwood PV. Structure, mechanism and regulation of pyruvate carboxylase. Biochem J. 2008;413(3):369–87.PubMedCentralPubMed

97.

Jitrapakdee S, Wallace JC. Structure, function and regulation of pyruvate carboxylase. Biochem J. 1999;340(Pt 1):1–16.PubMed

98.

St Maurice M, Reinhardt L, Surinya KH, Attwood PV, Wallace JC, Cleland WW, et al. Domain architecture of pyruvate carboxylase, a biotin-dependent multifunctional enzyme. Science. 2007;317(5841):1076–9.PubMed

99.

Cheng T, Sudderth J, Yang C, Mullen AR, Jin ES, Mates JM, et al. Pyruvate carboxylase is required for glutamine-independent growth of tumor cells. Proc Natl Acad Sci U S A. 2011;108(21):8674–9.PubMedCentralPubMed

100.

Fan TW, Lane AN, Higashi RM, Farag MA, Gao H, Bousamra M, et al. Altered regulation of metabolic pathways in human lung cancer discerned by (13)C stable isotope-resolved metabolomics (SIRM). Mol Cancer. 2009;8:41.PubMedCentralPubMed

101.

Forbes NS, Meadows AL, Clark DS, Blanch HW. Estradiol stimulates the biosynthetic pathways of breast cancer cells: detection by metabolic flux analysis. Metab Eng. 2006;8(6):639–52.PubMed

102.

Liu KJ, Kleps R, Henderson T, Nyhus L. 13C NMR study of hepatic pyruvate carboxylase activity in tumor rats. Biochem Biophys Res Commun. 1991;179(1):366–71.PubMed

103.

Zeczycki TN, Maurice MS, Attwood PV. Inhibitors of pyruvate carboxylase. Open Enzym Inhib J. 2010;3:8–26.PubMedCentralPubMed

104.

Bahl JJ, Matsuda M, DeFronzo RA, Bressler R. In vitro and in vivo suppression of gluconeogenesis by inhibition of pyruvate carboxylase. Biochem Pharmacol. 1997;53(1):67–74.PubMed

105.

Scrutton MC. Pyruvate carboxylase. Studies of activator-independent catalysis and of the specificity of activation by acyl derivatives of coenzyme A for the enzyme from rat liver. J Biol Chem. 1974;249(22):7057–67.PubMed

106.

Scrutton MC, Fatebene F. Inhibition of rat liver pyruvate carboxylase by acetoacetyl-CoA. FEBS Lett. 1976;62(2):220–5.PubMed

107.

Keech B, Barritt GJ. Allosteric activation of sheep kidney pyruvate carboxylase by the magnesium ion (Mg2+) and the magnesium adenosine triphosphate ion (MgATP2-). J Biol Chem. 1967;242(9):1983–7.PubMed

108.

Tonon FA, Kemmelmeier FS, Bracht A, Ishii-Iwamoto EL, Nascimento EA. Metabolic effects of oxalate in the perfused rat liver. Comp Biochem Physiol B Biochem Mol Biol. 1998;121(1):91–7.PubMed

109.

Thonpho A, Rojvirat P, Jitrapakdee S, MacDonald MJ. Characterization of the distal promoter of the human pyruvate carboxylase gene in pancreatic beta cells. PLoS One. 2013;8(1):e55139.PubMedCentralPubMed

110.

Wang D, Yang H, De Braganca KC, Lu J, Yu Shih L, Briones P, et al. The molecular basis of pyruvate carboxylase deficiency: mosaicism correlates with prolonged survival. Mol Genet Metab. 2008;95(1–2):31–8.PubMedCentralPubMed

111.

Jitrapakdee S, Gong Q, MacDonald MJ, Wallace JC. Regulation of rat pyruvate carboxylase gene expression by alternate promoters during development, in genetically obese rats and in insulin-secreting cells. Multiple transcripts with 5′-end heterogeneity modulate translation. J Biol Chem. 1998;273(51):34422–8.PubMed

112.

Jitrapakdee S. Transcription factors and coactivators controlling nutrient and hormonal regulation of hepatic gluconeogenesis. Int J Biochem Cell Biol. 2012;44(1):33–45.PubMed

113.

Thonpho A, Sereeruk C, Rojvirat P, Jitrapakdee S. Identification of the cyclic AMP responsive element (CRE) that mediates transcriptional regulation of the pyruvate carboxylase gene in HepG2 cells. Biochem Biophys Res Commun. 2010;393(4):714–9.PubMed

114.

Herzig S, Long F, Jhala US, Hedrick S, Quinn R, Bauer A, et al. CREB regulates hepatic gluconeogenesis through the coactivator PGC-1. Nature. 2001;413(6852):179–83.PubMed

115.

Le Lay J, Tuteja G, White P, Dhir R, Ahima R, Kaestner KH. CRTC2 (TORC2) contributes to the transcriptional response to fasting in the liver but is not required for the maintenance of glucose homeostasis. Cell Metab. 2009;10(1):55–62.PubMedCentralPubMed

116.

Rojvirat P, Chavalit T, Muangsawat S, Thonpho A, Jitrapakdee S. Functional characterization of the proximal promoter of the murine pyruvate carboxylase gene in hepatocytes: role of multiple gc boxes. Biochim Biophys Acta. 2011;1809(10):541–8.PubMed

117.

Chavalit T, Rojvirat P, Muangsawat S, Jitrapakdee S. Hepatocyte nuclear factor 4alpha regulates the expression of the murine pyruvate carboxylase gene through the HNF4-specific binding motif in its proximal promoter. Biochim Biophys Acta. 2013;1829(10):987–99.PubMed

118.

Louet JF, Chopra AR, Sagen JV, An J, York B, Tannour-Louet M, et al. The coactivator SRC-1 is an essential coordinator of hepatic glucose production. Cell Metab. 2010;12(6):606–18.PubMedCentralPubMed

119.

Jitrapakdee S, Slawik M, Medina-Gomez G, Campbell M, Wallace JC, Sethi JK, et al. The peroxisome proliferator-activated receptor-gamma regulates murine pyruvate carboxylase gene expression in vivo and in vitro. J Biol Chem. 2005;280(29):27466–76.PubMed

120.

Sunyakumthorn P, Boonsaen T, Boonsaeng V, Wallace JC, Jitrapakdee S. Involvement of specific proteins (Sp1/Sp3) and nuclear factor Y in basal transcription of the distal promoter of the rat pyruvate carboxylase gene in beta-cells. Biochem Biophys Res Commun. 2005;329(1):188–96.PubMed

121.

Pedersen KB, Buckley RS, Scioneaux R. Glucose induces expression of rat pyruvate carboxylase through a carbohydrate response element in the distal gene promoter. Biochem J. 2010;426(2):159–70.PubMed

122.

Kendrick AA, Choudhury M, Rahman SM, McCurdy CE, Friederich M, Van Hove JL, et al. Fatty liver is associated with reduced SIRT3 activity and mitochondrial protein hyperacetylation. Biochem J. 2011;433(3):505–14.PubMedCentralPubMed

123.

Yang J, Reshef L, Cassuto H, Aleman G, Hanson RW. Aspects of the control of phosphoenolpyruvate carboxykinase gene transcription. J Biol Chem. 2009;284(40):27031–5.PubMed

124.

Burgess SC, He T, Yan Z, Lindner J, Sherry AD, Malloy CR, et al. Cytosolic phosphoenolpyruvate carboxykinase does not solely control the rate of hepatic gluconeogenesis in the intact mouse liver. Cell Metab. 2007;5(4):313–20.PubMedCentralPubMed

125.

She P, Burgess SC, Shiota M, Flakoll P, Donahue EP, Malloy CR, et al. Mechanisms by which liver-specific PEPCK knockout mice preserve euglycemia during starvation. Diabetes. 2003;52(7):1649–54.PubMed

126.

Koo SH, Flechner L, Qi L, Zhang X, Screaton RA, Jeffries S, et al. The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature. 2005;437(7062):1109–11.PubMed

127.

Groen AK, van Roermund CW, Vervoorn RC, Tager JM. Control of gluconeogenesis in rat liver cells. Flux control coefficients of the enzymes in the gluconeogenic pathway in the absence and presence of glucagon. Biochem J. 1986;237(2):379–89.PubMed

128.

Groen AK, Vervoorn RC, Van der Meer R, Tager JM. Control of gluconeogenesis in rat liver cells. I. Kinetics of the individual enzymes and the effect of glucagon. J Biol Chem. 1983;258(23):14346–53.PubMed

129.

Samuel VT, Beddow SA, Iwasaki T, Zhang XM, Chu X, Still CD, et al. Fasting hyperglycemia is not associated with increased expression of PEPCK or G6Pc in patients with Type 2 Diabetes. Proc Natl Acad Sci U S A. 2009;106(29):12121–6.PubMedCentralPubMed

130.

Kumashiro N, Beddow SA, Vatner DF, Majumdar SK, Cantley JL, Guebre-Egziabher F, et al. Targeting pyruvate carboxylase reduces gluconeogenesis and adiposity and improves insulin resistance. Diabetes. 2013;62(7):2183–94.PubMed

131.

Owen MR, Halestrap AP. The mechanisms by which mild respiratory chain inhibitors inhibit hepatic gluconeogenesis. Biochim Biophys Acta. 1993;1142(1–2):11–22.PubMed

132.

Gonzalez-Manchon C, Ayuso MS, Parrilla R. Control of hepatic gluconeogenesis: role of fatty acid oxidation. Arch Biochem Biophys. 1989;271(1):1–9.PubMed

133.

Wimhurst JM, Manchester KL. Some aspects of the kinetics of rat liver pyruvate carboxylase. Biochem J. 1970;120(1):79–93.PubMed

134.

Robinson BH. Lactic acidemia and mitochondrial disease. Mol Genet Metab. 2006;89(1–2):3–13.PubMed

Titel: Regulation of pyruvate metabolism in metabolic-related diseases
verfasst von: Nam Ho Jeoung
Chris R. Harris
Robert A. Harris
Publikationsdatum: 01.03.2014
Verlag: Springer US
Erschienen in: Reviews in Endocrine and Metabolic Disorders / Ausgabe 1/2014
Print ISSN: 1389-9155
Elektronische ISSN: 1573-2606
DOI: https://doi.org/10.1007/s11154-013-9284-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2014

Risk of postprandial insulin resistance: The liver/vagus rapport

Adipose tissue inflammation in glucose metabolism

Autophagy as a crosstalk mediator of metabolic organs in regulation of energy metabolism

Genetic models of PGC-1 and glucose metabolism and homeostasis

Role of protein tyrosine phosphatases in the modulation of insulin signaling and their implication in the pathogenesis of obesity-linked insulin resistance

Roles of adiponectin and oxidative stress in obesity-associated metabolic and cardiovascular diseases